PubMed Health⌕ Search

Biomedical subjects

K Gondorowicz

Publications and source records attributed to K Gondorowicz.

At least 19 recordsLinked to original sources
PubMed1996

[Bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and the influence of loratadine and beclomethasone on this hyperresponsiveness].

60 patients aged 16 to 46 years with seasonal allergic rhinitis were selected for study. Daily symptom scores of seasonal allergic rhinitis and nonspecific bronchial hyperresponsiveness to histamine (PC20H in mg/ml) before, during the pollen season and after 3 weeks of treatment with loratadine, beclomethasone dipropionate were evaluated. The control group received oxymetazoline. Nonspecific bronchial hyperresponsiveness for 11 patients (18.3%) before the seasons was observed. At the beginning of the season frequency of nonspecific bronchial hyperresponsiveness increased to 26.3% and to 36.8% after 3-week treatment course. Bronchial hyperresponsiveness was not related to any of the way of treatment. The patients treated with beclomethasone dipropionate and oxymetazoline showed significant relief of nasal symptoms. The patients without bronchial hyperresponsiveness showed lower value of symptom scores.

Adolescent↗
PubMed1996

[The effect of bronchial allergen provocation on spontaneous production of histamine releasing factor (HRF) by mononuclear cells in patients with bronchial asthma].

The study was performed in 8 patients suffering from mild asthma. Bronchial allergen challenges with Dermatophagoides pretonyssinus were performed according to Chai et al method. Nonspecific bronchial reactivity to histamine (PC20H in mg/ml) were determined before the allergen challenge and in 90 min. and 24 hrs. after allergen provocation. Blood samples for mononuclear cells culture were collected before the trial and after the allergen challenge in 15, 90 min. and 8 and 24 hrs. The supernatants were assayed for HRF activity with basophils from a single donor. The significant increase of PC20H was observed xgPC20H in mg/ml 0.43 before allergen challenge and 0.08 and 0.125 after allergen provocation. Blood samples did not reveal any significant changes in HRF % activity--mean and SD before challenge test 47.7 16.2 and 49.9 15.0 in 15 min, 53.3 19.0 in 90 min, 56.6 15.8 in 8 hr, 52.5 20.4 in 24 hr after allergen provocation. The correlation between postallergen, nonspecific bronchial reactivity and spontaneous production of HRF activity was not found. The authors discuss the role of HRF in pathogenesis of nonspecific bronchial reactivity of asthmatic patients.

Adult↗
PubMed1995

[Course of non-specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma].

Bronchial hyperresponsiveness is the characteristic feature of bronchial asthma. Inhalation of allergen can cause dual asthmatic response--early and late reaction. Thirteen patients with mild and moderate asthma underwent bronchial allergen challenge. Non-specific bronchial reactivity was measured before, 90 minutes, on the 2nd, 7th, 14th day after provocation. Peak Expiratory Flow was measured every hour during 12 hours after challenge to search for late phase reaction. Increased bronchial reactivity was discovered as early as 90 minutes after challenge, it was still observed on the 2nd and 7th but not on the 14th day after allergen provocation. No relationship was found between appearance of late asthmatic reaction and increased bronchial reactivity.

Adult↗
PubMed1995

[Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction].

The aim of this study was to assess the duration of Loratadine effect on histamine H1 receptor in the airway. Six patients with mild or moderate asthma were examined. Bronchial reactivity to histamine was measured according to Cockcroft. The significant blockade of histamine H1 receptors in airway was observed from the 2nd day when 10 mg of Lo was given daily. The maximal protection with 10 mg doses was observed after 3-4 days. After another 5-6 days without Loratadine bronchial responsiveness return to the initial values. Single dose of 30 mg Loratadine given better protection against histamine bronchoconstriction than 10 mg given for 5 days. This effect was observed as early as 60 minutes after administration of Loratadine.

Adult↗
PubMed1992

[Effect of loratadine--selective antagonist of histamine (H1) receptor--on allergen-induced bronchoconstriction in atopic asthmatics].

The aim of this study was to evaluate the effect of loratadine on allergen-induced bronchoconstriction. The study was performed in 7 asthmatic patients with sensitivity to Dermatophagoides pteronyssinus, 4 women and 3 men. aged from 19 to 37 years. The allergen inhalatory--challenge test was performed according to Chai et al. Early phase of Dermatophagoides pteronyssinus--induced bronchoconstriction appeared in all examined patients, but late phase of bronchial obstruction was observed only in 3 persons. 30 mg orally administered of loratadine have no protect effect on early phase of allergen--induced bronchoconstriction. After loratadine ingestion the late phase of this bronchial obstruction disappeared.

Adult↗
PubMed1992

[Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction].

The influence of single and repeated LO (10 mg/day) doses on histamine-induced bronchoconstriction was studied in 11 patients with stabile bronchial asthma. Bronchial reactivity was estimated as histamine content potent to elicit a 20% FEV, fall, i.e. PC20H. A single dose gave a significant (5.5 fold) reduction in bronchial reactivity to inhaled histamine. Application of LO during 6 days gave a similar effect. Withdrawal of LO for 6 days yielded an increase in bronchial hyperreactivity.

Adult↗
PubMed1981

[Relationship between work in nitrogen-processing plants and chronic bronchitis including bronchial hypersensitivity].

The examination involved 55 men exposed to NH3, 60 exposed to NO2 and NH3 and 98 controls. Symptoms of chronic cough and (or) expectoration were found in 8 controls and 18 exposed workers. Significant differences refer only to smokers. Bronchial overreactivity was found in 23.5% controls and in 21.1% of those exposed. The authors conclude that in smokers exposed to NO2 and NH3 chronic bronchitis prevalence is greater whereas occupational exposure did not contribute to an increased number of those suffering from bronchial overreactivity.

Adult↗